This report describes the treatment of six patients with Cushing's disease of hypothalamic-pituitary origin, in whom the diagnosis was established by routine criteria. The patients were treated with one or other of the adrenocortical enzyme inhibitors, metyrapone and aminoglutethimide (Hughes & Burley 1970) , to render them clinically and biochemically euadrenal. At the same time megavoltage therapy (4-6 million volts) was given to the pituitary in a mean dose of 4600 rad over 31 days. The field arrangement was: 1 vertex and 2 lateral with each field measuring 4 x 4 cm.
Six patients, four women and two men aged from 30 to 48 years, were followed for a mean time of 17.5 months (4.5-26). Treatment was monitored by measurement of urinary free 11hydroxycorticosteroids (Mattingly 1962 ) ('cortisol'), plasma ACTH and plasma 11-hydroxycorticosteroids ('cortisol').
Biochemical control, in the form of low normal urinary free cortisol measurements, could be achieved within two weeks, and this was associated with subsequent remission of the clinical features of hyperadrenalism.
The effect of treatment on biochemical measurements is shown in Table 1 . The patients' clinical status appeared to correlate most closely with the results of the urinary free cortisol. In the first 3 cases treatment with adrenal blocking agents has been withdrawn and a sustained remission has occurred. In the second 3 cases relapse of the Cushing's syndrome occurred after withdrawal of blocking agents and treatment has been reinstituted. In one of the latter 3 cases adrenal blocking agents had only been given for six months which is probably insufficient time for the radiation effects on the pituitary to become manifest. Details of each patient's treatment are shown in Fig 1. Side-effects of treatment included seven minor episodes of hypoadrenalism and three episodes requiring admission to hospital. To obviate the risk of hypoadrenalism, dexamethasone is now given routinely along with adrenal blocking drugs. Severe itching occurred in 3 out of 6 cases given aminoglutethimide and necessitated withdrawal of the drug. One of the three had psoriasis. The doses at which this occurred ranged from 0.75 to 1.5 g/day. The patients who did not itch received identical doses. Severe depression was observed in one patient when he was rendered euadrenal. All patients treated with aminoglutethimide were given L-thyroxine because of the known antithyroid actions of this drug. Since aminoglutethimide also blocks aldosterone biosynthesis it is probably wise to prescribe a small dose of fludrocortisone when this drug is given, though this was not a routine procedure in this investigation.
We have-demonstrated that it is possible to render patients with Cushing's disease euadrenal with adrenal blocking drugs. In view of the hazards of adrenalectomy in patients with Cushing's syndrome, particularly if this is severe, it would seem reasonable to render all patients euadrenal before operation. Adrenal blocking therapy can also be used to maintain the euadrenal state while megavoltage therapy is given to the pituitary to halt the primary disease process. It is possible to induce a sustained remission of the Cushing's disease in some patients by this regime.
